Types of diabetes and their implications regarding heart and vascular disease

Medical Management of Diabetes and Heart Disease

Volumn , Issue , 2002, Pages 9-33

  Lebovitz, Harold E ^a  

^a Downstate Health Sciences University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0043190249     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (86)

1. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2001; 24(suppl 1): S5-S20.
2. Wingard DL, Barrett-Cannor E. Heart disease and diabetes. In: Diabetes in America, 2nd ed. NIH Publication No. 95-1468, 1995: 429-448.
3. Tuomilehto J, Rastenyté D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. In: Alberti KGMM, Zimmet P, DeFronzo RA, Keen H, eds. International Textbook of Diabetes Mellitus, 2nd ed. Chichester: John Wiley & Sons Ltd, 1997: 1559-1583.
4. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care 1999; 22: 659-660.
5. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
6. Banerji MA, Lebovitz HE. Insulin sensitive and insulin resistant variants in NIDDM. Diabetes 1989; 38: 784-792.
7. Banerji MA, Lebovitz HE. Coronary heart disease risk factor profiles in black patients with non-insulin-dependent diabetes mellitus: paradoxic patterns. Am J Med 1991; 91: 51-58.
8. Lebovitz HE, Banerji MA, Chaiken RL. The relationship between type II diabetes and syndrome X. Curr Opin Endocrinol Diabetes 1995; 2: 307-312.
9. Stern M. The insulin resistance syndrome. In: Alberti KGMM, Zimmet P, DeFronzo RA, Keen H, eds. International Textbook of Diabetes Mellitus, 2nd ed. Chichester: John Wiley & Sons Ltd, 1997: 255-283.
10. Lebovitz HE. Insulin resistance: Definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109(suppl 2): S135-S148.
11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
12. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure results from the DCCT. JAMA 1998; 280: 140-146.
13. King GL, Wakasaki H. Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 1999; 22(suppl 3): C31-C37.
14. Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LMB, Christlieb AR. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991; 90(suppl 2A): 56S-61S.
15. Orchard TJ, Stevens LK, Forrest KY-Z, Fuller JH. Cardiovascular disease in insulin dependent diabetes mellitus: Similar rates but different risk factors in the US compared with Europe. Int J Epidemiol 1998; 27: 976-983.
16. Kolvisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B, The EURODIAB IDDM Complications Study Group. Cardiovascular disease and its risk factors in IDDM in Europe. Diabetes Care 1996; 19: 689-697.
17. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, et al. Magnitude and determinants of coronary heart disease in juvenile-onset insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-755.
18. Fiorina P, LaRocca E, Venturini M, Minicucci F, Fermo I, Paroni R, D’Angelo A, Sblendido M, Di Carlo V, Cristallo M, Del Maschio A, Pozza G, Secchi A. Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes 2001; 50: 496-501.
19. Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 1999; 19: 1014-1019.
20. Isomma B, Almgren P, Henricsson M, Taskinen M, Tuomi T, Groop L, Sarelin L. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999; 22: 1347-1353.
21. Williams KV, Erbey JR, Becker D, Orchard TJ. Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. Diabetes Care 1999; 22: 1084-1091.
22. Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes: A systematic review and meta-analysis. Diabetes Care 1999; 22(suppl 2): B35-B39.
23. Lebovitz HE. The effect of the postprandial state on nontraditional risk factors. Am J Cardiol 2001; 88(Suppl): 20H-25H.
24. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 1998; 21: 610-614.
25. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000; 49: 626-632.
26. Orchard TJ, Forrest KY-Z, Kuller LH, Becker DJ. Lipid and blood pressure treatment goals for type 1 diabetes: 10 year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001; 24: 1053-1059.
27. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56: 265-294.
28. Bavdekar A, Chittaranjan S, Yajnik S, Fall CHD, Bapat S, Pandit AN, Deshpande V, Bhave S, Kellingray SD, Joglekar C. Insulin resistance syndrome in 8-year-old Indian children. Diabetes 1999; 48: 2422-2429.
29. Montague CT, O’Rahilly S. The perils of portliness. Causes and consequences of visceral adiposity. Diabetes 2000; 49: 883-888.
30. Banerji MA, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin resistant or insulin sensitive. Diabetes 1995; 44: 141-146.
31. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997; 273E: 425-432.
32. Banerji MA, Buckley C, Chaiken RL, Gordon D, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obesity 1995; 19: 846-850.
33. Pan DA, Lillioja S, Kritketos AD, Milner MR, Bauer LA, Bogardus C, Jenkins AB, Storlien LH. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46: 983-988.
34. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease and impaired glucose tolerance: The Whitehall Study. Lancet 1980; I: 1373-1376.
35. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: The Paris Prospective Study, ten years later. Horm Metab Res 1985; 15(suppl): 41-46.
36. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
37. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975-980.
38. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M-R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
39. Yamada N, Yoshinaga H, Sakurai N, Shimano H, Gotoda T, Ohashi Y, Yazaki Y, Kosaka K. Increased risk factors for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance. Diabetes Care 1994; 17: 107-114.
40. DECODE study group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. Br Med J 1998; 317: 371-375.
41. DECODE study group. Consequences of the new diagnostic criteria for diabetes in older men and women. The DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care 1999; 22: 1667-1671.
42. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924.
43. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998; 98: 2513-2519.
44. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited: Metabolic studies on offspring of diabetic probands. J Clin Invest 1998; 101: 86-96.
45. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001; 86: 1020-1025.
46. Haffner SM, D’Agostino RD Jr, Mykkänen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF. Insulin sensitivity in subjects with type 2 diabetes: Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-568.
47. U.K. Prospective Diabetes Study Group. UK Prospective Diabetes Study XII: Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabetes Med 1994; 11: 670-677.
48. U.K. Prospective Diabetes Study Group. Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32). Diabetes Care 1998; 21: 1271-1277.
49. Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged me. The 22-year follow-up results of the Helsinki policemen study. Arterioscler Thromb Vasc Biol 2000; 20: 538-544.
50. Lempiäinen P, Mykkänen L, Pyörälä K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100: 123-128.
51. Després J-P. The insulin resistance-dyslipidemia syndrome: The most prevalent cause of coronary artery disease? Can Med Assoc J 1993; 148: 1339-1340.
52. Lamarche B, Tchernof A, Mauriége P, Cantin B, Degenais GR, Lupien PJ, Després J-P. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-1961.
53. Kannel WB. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107.
54. Kannel WB, D’Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and the risk of cardiovascular disease: The Framingham experience. Am Heart J 1999; 120: 672-676.
55. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
56. Danesh J. Smoldering arteries? Low-grade inflammation and coronary heart disease. JAMA 1999; 282: 2169-2170.
57. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482.
58. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22(suppl 3): C10-C13.
59. Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. PNAS(USA) 2000; 92: 11371-11376.
60. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. Genes Devel 1998; 12: 3168-3181.
61. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550.
62. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
63. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
64. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
65. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103: 931-943.
66. Dib K, Whitehead JP, Humphreys PJ, Soos MA, Baynes KCR, Kumar S, Harvey T, O’Rahilly S. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly: A disorder characterized by selective postreceptor insulin resistance. J Clin Invest 1998; 101: 1111-1120.
67. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocrine Rev 2001; 22: 36-52.
68. Zeng G, Nystrom FH, Ravichandran LV, Cong L-N, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI 3-kinase, and Akt in insulin-signaling pathways related to production of nitris oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-1545.
69. Thomas GD, Ahang W, Victor RG. Nitric oxide deficiency as a cause of clinical hypertension: Promising new drug targets for refractory hypertension. JAMA 2001; 285: 2055-2057.
70. Tooke JE. Endotheliopathy precedes type 2 diabetes. Diabetes Care 1998; 21: 2047-2049.
71. Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V, Denver AE. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II Diabetic subjects. Diabetologia 2000; 43: 1099-1106.
72. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999; 22(suppl 3): C25-C30.
73. Carr ME. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
74. Meigs JBJ, Mittleman MA, Nthan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000; 283: 221-228.
75. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-2135.
76. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
77. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-1710.
78. Feingold KR, Grunfeld C, Pang M, Doerrier W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992; 12: 1496-1502.
79. Festa A, D’Agostino R Jr, Mykkänen L, Tracy RP, Hales CN, Howard BV, Haffner SM. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. Diabetes Care 1999; 22: 1688-1693.
80. Ginsberg HN, Tuck C. Diabetes and dyslipidemia. In: Lebovitz HE, ed. Educational Review Manual in Endocrinology and Metabolism. New York: Castle Connolly Graduate Medical Publishing, 2000: 1-47.
81. Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The Insulin Resistance Atherosclerosis Study. Diabetes 1998; 47: 793-800.
82. Wagenknecht LE, D’Agostino RB Jr, Haffner SM Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: The Insulin Resistance Atherosclerosis Study. Diabetes Care 1998; 21: 1812-1818.
83. Laakso M, Rönnemaa T, Lehto S, Puukka P, Kallio V, Pyörälä K. Does NIDDM increase the risk for coronary heart disease similarly in both low-and high-risk populations? Diabetologia 1995; 38: 487-493.
84. Liu QZ, Knowler WC, Nelson RG, Saad MS, Charles MA, Liebow IM, Bennett PH, Pettitt DJ. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Cross-sectional and prospective analyses. Diabetes 1992; 41: 1141-1150.
85. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
86. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O’Leary DH, Savage PJ. Diabetes mellitus: Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 2000; 20: 823-829.